Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma

References

• Brody JD, Ai WZ, Czerwinski DK et al.In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol.28(28), 4324–4332 (2010).
   PubMed Web of Science ®Google Scholar
• Pashenkov M, Goess G, Wagner C et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol.24(36), 5716–5724 (2006).
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Ansen S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res.11(16), 5993–6001 (2005).
   PubMed Web of Science ®Google Scholar
• Kim Y GM, McAuley S, Schmalbach T. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CpG immunomodulator (CPG 7909), a Phase I study. J. Clin. Oncol.22(14S), (2004) (Abstract 6600).
   Google Scholar
• Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter Phase I/II study. Clin. Genitourin. Cancer7(3), E58–E65 (2009).
   PubMed Web of Science ®Google Scholar
• Link BK, Ballas ZK, Weisdorf D et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother.29(5), 558–568 (2006).
   PubMed Web of Science ®Google Scholar
• Manegold C, Gravenor D, Woytowitz D et al. Randomized Phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(24), 3979–3986 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Song W, Czerwinski DK et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol.179(4), 2493–2500 (2007).
   PubMed Web of Science ®Google Scholar
• Meng Y, Carpentier AF, Chen L et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer116(6), 992–997 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med.2(1), 52–58 (1996).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood89(9), 3129–3135 (1997).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med.327(17), 1209–1215 (1992).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood99(5), 1517–1526 (2002).
   PubMed Web of Science ®Google Scholar
• Inoges S, Rodriguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst.98(18), 1292–1301 (2006).
   PubMed Web of Science ®Google Scholar
• Levy R RM, Leonard J, Vose J, Denney D. Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (ID) conjugated to KLH (ID-KLH) with GM-CSF, compared to non specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin lymphoma (FNHL). Ann. Oncol.19 (2008) (Abstract 57).
   Google Scholar
• Hus I, Rolinski J, Tabarkiewicz J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia19(9), 1621–1627 (2005).
   PubMed Web of Science ®Google Scholar
• Berard F, Blanco P, Davoust J et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med.192(11), 1535–1544 (2000).
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Zappasodi R, Carlo-Stella C et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood113(1), 18–27 (2009).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov.5(6), 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J. Clin. Invest.117(5), 1184–1194 (2007).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kim H, McCauley M et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood105(2), 489–495 (2005).
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen- presenting cells: potential for clinical application. Blood99(9), 3319–3325 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo E, Gryschok L, Klein-Gonzalez N et al. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin. Exp. Immunol.155(2), 249–256 (2009).
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous Toll-like receptor 9 stimulation. J. Transl. Med.7, 93 (2009).
   PubMed Web of Science ®Google Scholar
• Ruter J, Antonia SJ, Burris HA 3rd, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a Phase I study of patients with advanced solid tumors. Cancer Biol. Ther.10(10), 983–993 (2010).
   PubMed Web of Science ®Google Scholar